Rivoceranib
Preoperative
The First Affiliated Hospital with Nanjing Medical UniversitySmall moleculePhase 3Active
B
60/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 45/ 100
- Competitive Position
- 89/ 100
Competitive context
4 Active assets in the Preoperative cohort.
Same molecule, other indications
Rivoceranib is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →